How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome
- 21 January 2021
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 137 (3) , 299-309
Abstract
The standard treatment of thrombotic antiphospholipid syndrome (APS) is lifelong oral anticoagulation with a vitamin K antagonist (VKA), generally warfarin. A minority of patients with APS rethrombose despite seemingly adequate anticoagulation. These patients are deemed anticoagulant refractory. The management of anticoagulant-refractory APS is largely empirical and extrapolated from other clinically similar situations. Further options include increased VKA anticoagulation intensity or alternative antithrombotic strategies, including low-molecular-weight heparin, fondaparinux, the addition of antiplatelet therapy, and consideration of vascular options. Patients with anticoagulant-refractory thrombotic APS may have APS-associated thrombocytopenia, which necessitates balancing the risk of recurrent thrombosis vs bleeding to achieve adequate anticoagulation. The multiple mechanisms involved in the generation of the thrombotic phenotype in APS suggest that anticoagulation alone may not control thrombosis. Thus, other modalities, including adjunctive treatment (hydroxychloroquine, statins, and vitamin D) for APS-related thrombosis, merit consideration, as do immunomodulatory therapy and complement inhibition. Patients with APS may have coexistent systemic lupus erythematosus, which adds to the complexity of managing their thromboembolic disease. However, with attention to detail and judicious application of the limited data, it is possible to minimize the morbidity resulting from anticoagulant-refractory thrombotic APS. Multicenter studies are required to guide the sequence of interventions and their comparative efficacy in patients with anticoagulant-refractory thrombotic APS.Keywords
This publication has 85 references indexed in Scilit:
- Guidelines on the investigation and management of antiphospholipid syndromeBritish Journal of Haematology, 2012
- Evidence-Based Management of Anticoagulant TherapyChest, 2012
- Oral Anticoagulant TherapyChest, 2012
- Thrombopoietin-Receptor Agonists for Immune ThrombocytopeniaNew England Journal of Medicine, 2011
- Clinical course of high‐risk patients diagnosed with antiphospholipid syndromeJournal of Thrombosis and Haemostasis, 2010
- Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patientsJournal of Thrombosis and Haemostasis, 2009
- B cell depletion therapy for patients with systemic lupus erythaematosus results in a significant drop in anticardiolipin antibody titresAnnals of the Rheumatic Diseases, 2008
- Once-daily fondaparinux monotherapy without warfarin for long-term treatment of venous thromboembolismThrombosis and Haemostasis, 2007
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Fluvastatin inhibits up‐regulation of tissue factor expression by antiphospholipid antibodies on endothelial cellsJournal of Thrombosis and Haemostasis, 2004